In short
Actinium (Ac 225) Oxodotreotide, also known as RYZ101, is being investigated in clinical trials for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This article provides an overview of the ongoing research, including the trial's objectives, eligibility criteria, and potential benefits for patients who have progressed after previous treatments.
At a glance
- Drug Name
- Actinium (Ac 225) Oxodotreotide (RYZ101)
- Trial Phase
- Phase 1b/3
- Target Condition
- Advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
- Patient Population
- Patients with inoperable, advanced, SSTR+ GEP-NETs that progressed after 177Lu-SSA therapy
- Primary Objectives
- Determine recommended dose, assess safety and tolerability, compare PFS to standard of care
- Secondary Objectives
- Evaluate overall survival, objective response rate, and quality of life measures
- Administration
- Intravenous injection
- Key Eligibility Criteria
- Adequate organ function, no recent major surgeries or radiation therapy, no brain metastases
- Safety Monitoring
- Adverse events, laboratory changes, ECG changes
What is ACTINIUM (AC 225) OXODOTREOTIDE?
ACTINIUM (AC 225) OXODOTREOTIDE, also known as RYZ101 or Ac-225 DOTATATE, is an innovative drug being studied for the treatment of advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This medication is classified as a targeted radionuclide therapy, which means it combines a radioactive element (Actinium-225) with a molecule that can specifically bind to cancer cells.
Medical Condition Treated
The primary focus of this treatment is on gastroenteropancreatic neuroendocrine tumors (GEP-NETs). These are rare tumors that form in the digestive system, including the pancreas, stomach, and intestines. Specifically, this drug is being studied for patients with: Inoperable, advanced GEP-NETs Tumors that express somatostatin receptors (SSTR+) Well-differentiated tumors (which means they grow slowly) Tumors that have progressed after previous treatment with another type of radionuclide therapy (177Lu-labelled somatostatin analogue therapy)
How It Works
ACTINIUM (AC 225) OXODOTREOTIDE works by targeting specific receptors called somatostatin receptors, which are often found in high numbers on the surface of neuroendocrine tumor cells. The drug consists of two main parts: DOTATATE: This is a molecule that binds specifically to somatostatin receptors on tumor cells. Actinium-225: This is a radioactive element that delivers radiation directly to the tumor cells. When the drug is injected into the bloodstream, it circulates throughout the body. The DOTATATE part of the drug seeks out and attaches to the somatostatin receptors on tumor cells. Once attached, the Actinium-225 emits radiation, which can damage and kill the cancer cells.
Current Clinical Trial
ACTINIUM (AC 225) OXODOTREOTIDE is currently being studied in a clinical trial called ACTION-1. This is a Phase 1b/3 global, randomized, controlled, open-label trial. Here are some key points about the trial: It compares RYZ101 (ACTINIUM (AC 225) OXODOTREOTIDE) to standard of care (SoC) therapy. The trial has two parts: Part 1: Focuses on determining the right dose and assessing safety. Part 2: Aims to determine if RYZ101 improves progression-free survival compared to standard treatments. The trial is looking at several outcomes, including overall survival, tumor response rates, and quality of life measures.
Eligibility Criteria
To participate in this clinical trial, patients must meet certain criteria. Some key eligibility factors include: Having a GEP-NET that has progressed after previous treatment with 177Lu-labelled somatostatin analogue therapy Adequate kidney function Adequate blood cell counts No history of certain other cancers within the past 3 years No brain metastases (in Part 2, previously treated brain metastases may be allowed under certain conditions) There are also several exclusion criteria, such as certain cardiovascular conditions, uncontrolled diabetes, and pregnancy or breastfeeding.
How It's Administered
ACTINIUM (AC 225) OXODOTREOTIDE is given as an intravenous (IV) injection. The maximum daily dose being studied is 10.2 MBq (megabecquerels, a unit of radioactivity), with a maximum total dose of 40.8 MBq over a treatment period of up to 32 weeks.
Potential Benefits
While the full benefits of ACTINIUM (AC 225) OXODOTREOTIDE are still being studied, researchers hope that it may offer several advantages over current treatments: Improved progression-free survival (time without the cancer growing or spreading) Better overall survival Higher tumor response rates Improved quality of life for patients with advanced GEP-NETs However, it's important to note that these potential benefits are still being evaluated in the clinical trial.
Safety Considerations
As with any new treatment, safety is a crucial consideration. The clinical trial is closely monitoring for any side effects or adverse events. Some specific safety measures include: Regular monitoring of blood cell counts, kidney function, and liver function Watching for any signs of heart problems Monitoring for any unexpected side effects Patients considering this treatment should discuss potential risks and benefits thoroughly with their healthcare provider.